MY203432A - Treatment and prophylaxis of amyloidosis - Google Patents

Treatment and prophylaxis of amyloidosis

Info

Publication number
MY203432A
MY203432A MYPI2020004912A MYPI2020004912A MY203432A MY 203432 A MY203432 A MY 203432A MY PI2020004912 A MYPI2020004912 A MY PI2020004912A MY PI2020004912 A MYPI2020004912 A MY PI2020004912A MY 203432 A MY203432 A MY 203432A
Authority
MY
Malaysia
Prior art keywords
treatment
amyloidosis
prophylaxis
antibody
deposition
Prior art date
Application number
MYPI2020004912A
Other languages
English (en)
Inventor
Tarlochan Nijjar
Iii Philip J Dolan
Robin Barbour
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of MY203432A publication Critical patent/MY203432A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2020004912A 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis MY203432A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862647341P 2018-03-23 2018-03-23
PCT/US2019/023528 WO2019183448A1 (en) 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis

Publications (1)

Publication Number Publication Date
MY203432A true MY203432A (en) 2024-06-27

Family

ID=66041747

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020004912A MY203432A (en) 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis

Country Status (13)

Country Link
US (1) US20210017278A1 (cg-RX-API-DMAC7.html)
EP (1) EP3768311A1 (cg-RX-API-DMAC7.html)
JP (1) JP7217287B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200143400A (cg-RX-API-DMAC7.html)
CN (1) CN112040983A (cg-RX-API-DMAC7.html)
AU (2) AU2019240413A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020019172A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095100A1 (cg-RX-API-DMAC7.html)
EA (1) EA202092264A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020009920A (cg-RX-API-DMAC7.html)
MY (1) MY203432A (cg-RX-API-DMAC7.html)
SG (1) SG11202009295YA (cg-RX-API-DMAC7.html)
WO (1) WO2019183448A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009086539A2 (en) * 2007-12-28 2009-07-09 Elan Pharmaceuticals, Inc. Treatment and prophylaxis of amyloidosis
BR112014009866A2 (pt) * 2011-10-25 2018-09-04 Onclave Therapeutics Limited formulações de anticorpos e métodos
RS63446B1 (sr) * 2016-06-30 2022-08-31 Prothena Biosciences Ltd Kompozicije za lečenje amiloidoze

Also Published As

Publication number Publication date
EA202092264A1 (ru) 2020-12-03
KR20200143400A (ko) 2020-12-23
EP3768311A1 (en) 2021-01-27
AU2019240413A1 (en) 2020-10-08
AU2023202109A1 (en) 2023-05-18
MX2020009920A (es) 2020-12-10
CN112040983A (zh) 2020-12-04
JP7217287B2 (ja) 2023-02-02
WO2019183448A1 (en) 2019-09-26
SG11202009295YA (en) 2020-10-29
BR112020019172A2 (pt) 2021-01-26
US20210017278A1 (en) 2021-01-21
JP2021518393A (ja) 2021-08-02
CA3095100A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
PH12020550694A1 (en) Lyophilized formulation of a monoclonal antibody against transthyretin
MY205789A (en) Anti-gdf15 antibodies, compositions and methods of use
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
EP3768721A4 (en) Novel anti-ctla-4 antibody polypeptide
PE20170665A1 (es) Anticuerpos anti-tau humanizados
PE20190737A1 (es) Anticuerpos anti-cd27
MX2017001531A (es) Anticuerpos anti-trem2 y metodos de uso de los mismos.
EP4327866A3 (en) Mirikizumab in the treatment of ulcerative colitis
AR096687A1 (es) Anticuerpos anti-fcrh5
MX2020003581A (es) Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas.
AU2015287227A8 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
EA201600277A1 (ru) Высокоаффиные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
WO2019117685A3 (ko) 항-igf1r 항체 및 그 용도
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
PE20230381A1 (es) Proteina de union a rgma
BR112017022073A2 (pt) método para purificação de proteína
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
EA201890340A1 (ru) Моноклональное антитело-ингибитор фактора xiia
JOP20200295A1 (ar) أجسام أحادية النوعية ومتعددة النوعية مضادة لـ tmeff2 المضاد واستخداماتها
WO2019152356A3 (en) Glucuronylation as acidic post-translational modification on therapeutic monoclonal antibodies
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof